Physician profile
Steven D Ebers
NPI 1578056800
$2,878.79
in general payments reported to CMS, 2019-2025
30 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.31 · 2021: $405 · 2022: $565 · 2023: $525 · 2024: $851 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.89 | 2021-2025 | Vraylar, Ubrelvy, Mavyret |
| Glaxosmithkline, LLC. | $227.40 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $199.30 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $192.31 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.01 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $143.68 | 2021-2025 | Rexulti, Nuedexta |
| Grifols USA, LLC | $125.89 | 2021-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $117.31 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.60 | 2021-2024 | Xifaxan |
| Pfizer INC. | $110.60 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $109.52 | 2021-2022 | |
| Indivior INC. | $79.91 | 2024-2025 | Sublocade |
| Aimmune Therapeutics, INC. | $70.36 | 2024-2025 | Zenpep, Vowst |
| Amgen INC. | $69.36 | 2022-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $61.69 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $48.24 | 2023-2024 | (8874) Incourage |
| Dexcom, INC. | $47.45 | 2024-2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $36.39 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $35.58 | 2025 | Uzedy |
| Paratek Pharmaceuticals, INC. | $29.57 | 2024 | Nuzyra |
| Axsome Therapeutics, INC. | $24.18 | 2022 | |
| Adlon Therapeutics L.P. | $19.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2023 | |
| Neurocrine Biosciences, INC. | $16.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $15.58 | 2025 | Gardasil 9, Capvaxive |
| Apria Healthcare LLC | $15.33 | 2021 | |
| Alkermes, INC. | $13.66 | 2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $13.57 | 2023 | Cologuard Collection Kit |
| Coopersurgical, INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ebers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.